Related Experiment Videos
[Carcinogenic activity of dioxidine]
Farmakologiia I Toksikologiia
|January 1, 1985
Summary
Dioxydin, a new broad-action antibacterial drug, was evaluated for carcinogenicity. Long-term administration to rodents at high doses did not result in any tumor development, indicating no blastomogenic activity.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Dioxydin is a novel antibacterial agent with broad-spectrum activity.
- Assessing the long-term safety and potential carcinogenicity of new drugs is crucial.
Purpose of the Study:
- To investigate the blastomogenic (cancer-inducing) potential of dioxydin.
- To evaluate the safety profile of dioxydin in preclinical models.
Main Methods:
- Rodents (mice and rats) were administered dioxydin orally and intraperitoneally for extended periods (up to 2 years).
- Transplacental and postnatal administration routes were also employed in rats.
- Dose levels used exceeded the human therapeutic dose by 2-10 fold.
Main Results:
- No evidence of neoplasm (tumor) formation was observed in any of the treatment groups.
- Dioxydin administration did not induce carcinogenic effects in mice or rats under the study conditions.
Conclusions:
- Dioxydin demonstrated a lack of blastomogenic activity in rodent models.
- These findings suggest a favorable safety profile regarding carcinogenicity for dioxydin.